All News

All News2019-03-07T14:47:33-02:30

BioVectra Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

BioVectra Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Winsor community stakeholders to discuss planned five-year, $144.6 million expansion project

Windsor, Nova Scotia, Canada (March 7, 2019) – On March 6, 2019, BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), hosted a roundtable discussion at its Windsor, Nova Scotia facility to discuss the local impact of the planned five-year, $144.6 million expansion project announced on March 4 in Charlottetown, PEI. Community roundtable voices included Bernadette Jordan, Minister of Rural Economic Development, the Atlantic Canadian Opportunity Agency (ACOA), Innovation, Science and Economic Development (ISED), municipal leaders including Mayors Anna Allen and Peter Muttart, key industry association leaders, Acadia University and Nova Scotia Community College (NSCC) representatives, and local business representatives.

In support of the expected $144.6 million expansion project, BioVectra received a $37.5 million investment through the Government of Canada’s Strategic Innovation Fund. Over the five-year lifespan of the project, the company intends to create 150 jobs in Atlantic Canada, with 110 anticipated in Windsor, Nova Scotia.

“We’re proud to be a partner with BioVectra in creating well-paying jobs here in the Maritimes. This funding will allow BioVectra to expand its manufacturing capacity and start research and development of advanced pharmaceutical products not currently manufactured in Canada, helping to position the Maritimes as an innovative hub for these products that save lives.” – The Honourable Bernadette Jordan, Minister of Rural Economic Development

The roundtable discussion focused on understanding and supporting the project itself, but also on leveraging the collective contributions and strengths of all stakeholders in creating a climate to capture and create more opportunities like this one for long-term regional growth. “This invaluable exchange was focused on community collaboration,” said BioVectra’s Windsor General Manager, Heather Delage. “This discussion was all about building momentum and bringing the right people to the table that can help create an environment and action plan to support our investment.”

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext. 6376
E-Mail: jmacgregor@biovectra.com


Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

March 7th, 2019|News|

BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

— Prime Minister Justin Trudeau visits BioVectra to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region —

Charlottetown, Prince Edward Island, Canada (March 4, 2019) – Today, BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), announced a five-year, $144.6 million (CAD) expansion project to enhance its Biopharmaceutical capabilities in both Charlottetown, Prince Edward Island and Windsor, Nova Scotia.

Prime Minister, Justin Trudeau, visited BioVectra in Charlottetown to announce a $37.5 million contribution from the Government of Canada through the Strategic Innovation Fund (SIF). The $37.5 million contribution represents the single largest SIF Project ever awarded in Atlantic Canada.

“Thanks to innovations in life sciences, Canadians are living longer, healthier lives than ever before. Canadian companies like BioVectra are creating new jobs and establishing themselves as global leaders in producing lifesaving treatments for serious illnesses that affect millions of people around the world. Today, we are not only investing in an innovative Canadian business, but also in Canadians and the future prosperity of our country.” – The Rt. Hon. Justin Trudeau, Prime Minister of Canada

More specifically, the project is intended to support BioVectra’s on-going Active Pharmaceutical Ingredients (APIs) production capacity expansion in Charlottetown, as well as an expansion of its Biologics capabilities in Windsor, including a mammalian cell culture facility.

Over the project’s five-year lifespan, 150 high-skilled, full-time jobs are expected to be created on Prince Edward Island and in Nova Scotia. “We are pleased to announce plans to create 150 additional jobs, 110 to be located at our Windsor site and 40 in Charlottetown,” said BioVectra President, Oliver Technow. “This is an extremely proud day for BioVectra, and we are deeply appreciative of the government’s support. Since 2015, we have invested approximately $25 million per year in expansions and technologies that have vastly enhanced our capabilities. Today’s announcement is a continuation of our commitment to growth right here in Atlantic Canada!”

As a trusted and innovative partner, BioVectra’s global client base includes most of the top 20 biopharmaceutical companies in the world. “Our clients develop important, life-saving medicines for people all around the globe,” said BioVectra’s Windsor General Manager, Heather Delage. “This exciting expansion project is designed to help propel us toward being a top-tier player in the biologics field, where many therapies are advancing rapidly, and changing the way healthcare is delivered.”

Beyond these expansion plans, BioVectra intends to complement its existing academic partnerships by forming additional collaborations with Canadian academic institutions. This investment includes reinforcing its future talent base by providing over 25 students with on-the-job training and internship opportunities on an annual basis.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext. 6376
E-Mail: jmacgregor@biovectra.com


Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

March 4th, 2019|News|

BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

BioVectra Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BioVectra Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD API for clinical and commercial applications. BioVectra’s efficient cGMP CBD manufacturing process allows for the production of hundreds of kilograms, with the ability to scale-up to multi-metric ton quantities. This scale-up and supporting regulatory experience is a key competency for BioVectra, which can be applied to additional cannabinoid derivatives. Production is on-going for intermediate-scale batches, with process validation and submission of a Drug Master File to follow.

Located in Canada, BioVectra is uniquely positioned as a global supplier of synthetic cGMP CBD. The company can offer material supply, as well as product storage services as required.

BioVectra has a history of working in cannabinoids, dating back to the early 2000s, when it developed a supply of dronabinol. Building off its existing strengths in complex synthetic chemistry and natural product purifications, the company’s ability to manufacture synthetic cGMP CBD complements increased market demand. BioVectra looks forward to continuing to supply its current and new customers with this pharmaceutically important compound.

For more information, please contact BioVectra at cbd@biovectra.com or 866-883-2872 to discuss your CBD requirements.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Contact

Fahim Naeem, Business Development Manager
BioVectra Inc.
Phone: 866-883-2872
E-Mail: cbd@biovectra.com

March 17th, 2019|News|

BioVectra Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BioVectra Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BioVectra completed the replacement of two 4,000L vessels used for small molecule synthesis.

“These vessels have been very important for advancing our clients’ programs into later-stage clinical trials,” said Matt Frizzle, BioVectra’s Director of Business Development, CMO Services. “They are highly critical when larger quantities of Active Pharmaceutical Ingredients (APIs) are needed and, in particular, through commercial supply.” For earlier stages of research, BioVectra operates several cGMP kilo labs, with access to reactors in the range of 30-800L.

Additionally, BioVectra announced an enhancement of its analytical capabilities through the purchase of new equipment. “These investments help ensure our process development team has adequate control and specifications to meet regulatory requirements,” said Dr. Marc Sauer, BioVectra’s Vice President of Research and Development.  BioVectra’s suite of analytical equipment will be bolstered with the addition of two UPLCs and five HPLCs, two Charged Aerosol Detectors (CAD), two single quad mass detectors, a XRPD unit, an ICP-MS, a particle surface area and a DSC/TGA instrument.

Combined these investments were in the order of $1.5M, and were made to enhance BioVectra’s overall API service offering to our global biotechnology and pharmaceutical partners.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor

Marketing and Communications Manager

jmacgregor@biovectra.com

902-566-9116 ext. 6376

March 15th, 2019|News|

Enhancing capabilities, hiring top-talent and growing our operations!

BioVectra announces five-year, $144.6m expansion project intended to support on-going API production capacity and enhancement of Biologics capabilities, including a mammalian cell culture facility. Over the lifespan of the project, 150 high-skilled, full-time jobs are expected to be created on Prince Edward Island and in Nova Scotia.

Additionally, BioVectra invests $1.5m in large-scale synthetic reactor replacements and analytical development capabilities.

Connect with us at DCAT Week (info@biovectra.com) to learn more about our exciting investments and growth!

March 7th, 2019|Uncategorised|

BioVectra wins BIOTECanada’s Gold Leaf Award for Company of the Year!

CANADIAN BIOTECH INDUSTRY RECOGNIZES TOP PERFORMERS DURING GLOBAL BIOTECH WEEK

September 26, 2018 [OTTAWA] – BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who have helped lead the industry throughout 2018.

“The remarkable individuals and companies we recognize through the Gold Leaf Awards are great examples of the core strengths of Canada’s biotech ecosystem including scientific excellence and passion,” commented Andrew Casey, President and CEO of BIOTECanada. “Importantly, Canada’s global biotech success is founded in its ability to advance scientific innovation by leveraging a diverse and vibrant ecosystem comprised of individuals, companies and institutions located in every province across the country. It is this strength that establishes Canada’s biotech industry as a leader in developing the solutions that will help address the global social and economic opportunities emerging from population growth and a changing climate.”

2018 BIOTECanada Gold Leaf Winners:

  • Aspect Biosystems Ltd. (Emerging Company of the Year)
  • BioVectra Inc. (Company of the Year)
  • CDRD – The Centre for Drug Research and Development (Ecosystem Builder)
  • Wilf Keller, CEO Ag-West Bio (Industry Leadership)

“To be selected as BIOTECanada’s Emerging Company of the Year, among so many notable biotech companies across the country, is a true honour,” said Tamer Mohamed, Aspect’s President and CEO. “We are inspired by the profound impact regenerative medicine therapies can have on patients around the globe and our team is committed to realizing this impact from right here in Canada.”

“On behalf of BioVectra, it is an honour to win BIOTECanada’s 2018 Gold Leaf Award for Biotech Company of the Year,” said Oliver Technow, President of BioVectra. “Our team has accomplished a lot over the past year. Our new biologics facility is now online in Windsor, Nova Scotia, we are making tremendous progress on an expansion at our headquarters in Charlottetown, Prince Edward Island, and we continue to build upon our capabilities, our development experience, and our technologies so that we can grow alongside our partners and help them advance their clinical programs efficiently. None of this would be possible without our highly dedicated and specialized employees. This award is truly a testament to their hard work and tenacity!”

“We are honoured that CDRD has been chosen to receive the BIOTECanada Gold Leaf Ecosystem Builder Award. This award is a testament to the tremendous dedication and hard work of each and every one of our team of 100+ scientists and business people; and the success they have achieved in commercializing innovation, attracting investment, supporting globally competitive Canadian companies; and helping generate long term, highly-skilled employment opportunities for Canadians – for moving us towards our Vision of being catalyst for Canada life sciences leading the world,” said Gordon C. McCauley, President and CEO of CDRD.

“It’s a great surprise and honour to receive the Gold Leaf Award from BioteCanada, an national entity that does the very important job coordinating and supporting biotech research. I’ve had the privilege of working with so many great people. It’s all about teamwork; I’ve been able to work with many excellent teams over the years. I look forward to continuing to contribute in any way I can.”

Global Biotech Week running September 24 – 30, 2018 brings together domestic and international biotechnology associations will experience hundreds of events across 20 countries. With thousands of participants each year, Global Biotech Week provides an opportunity to collaborate and showcase the impact biotechnology is having on economies celebrating science, innovation, and solutions.

September 26th, 2018|News|

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation

Whitepaper: An Innovative Approach to Manufacturing Biologics Using Microbial Fermentation

Overview


The use of microbial fermentation to make biologics is growing rapidly. A manufacturing platform is an increasingly popular way to speed up process development stages and get a biologic to market faster. High-throughput systems can speed up optimization of each of these platform steps. Single-use, disposable technologies are starting to replace stainless steel to streamline biologic manufacturing, reduce costs, minimize contamination risks and allow rapid expansion of capacity.

Key Learning Objectives

  • What a platform technology is and how it can speed up process development.
  • How high-throughput technologies can be used in biologic process development.
  • What single-use, disposable technologies are currently on the market for biologics manufacturing and the advantages of using them.

Brought to you by

BioVectra logo

Please complete the form to download the whitepaper.
Please select all that apply.
Please select all that apply.
August 1st, 2018|Articles|

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

BioVectra and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

16/07/18 – CHARLOTTETOWN, Prince Edward Island, Canada – Today, BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO) with microbial fermentation and synthesis capabilities with high containment, and TUBE Biopharmaceuticals GmbH, an Austrian biotech company active in the research field of cytotoxic payloads, announced that they have signed an exclusive license agreement for microbial fermentation technology to manufacture tubulysins.

After conducting further development, optimization and upscaling of the strain initially developed by TUBE Biopharmaceuticals, BioVectra intends to provide the marketplace with research- and cGMP-grade tubulysins and downstream derivatives.

Tubulysins belong to a cytotoxic tetrapeptidic natural product class that result in disruption of microtubule networks and inhibition of tubulin polymerization of cancer cells, and are suitable for use in conjugation approaches such as Antibody Drug Conjugates (ADCs), specifically targeting drug-resistant cancers.

Financial details of this unlimited agreement were not disclosed.

For more information, please contact Jordan MacGregor, at jmacgregor@biovectra.com.

About BioVectra

BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development

For more information about BioVectra, please visit www.biovectra.com.

About TUBE Biopharmaceuticals

TUBE Pharmaceuticals GmbH (www.tubepharma.de) was founded in January 2011 in Austria having its labs in Vienna. TUBE Pharmaceuticals develops and commercializes drug candidates derived from natural products with high potency for novel therapeutic applications in the field of oncology. Together with advanced targeting approaches safer and more efficacious therapies especially preventing tumor resistance are to be expected for patients. In-licensing opportunities in the field of natural products derived oncology drugs closer to the clinics complement the internally developed assets of the Company and help to transform the Company into an oncology development company with an attractive pipeline to create further value.

July 16th, 2018|News, Uncategorised|

Windsor Expansion Helps BioVectra Meet Global Market Demand

Windsor Expansion Helps BioVectra Meet Global Market Demand

Extensive facility renovation, new equipment, assists life sciences firm in creating jobs, growing regional economy

April 12, 2018 – Windsor, NS – Atlantic Canada Opportunities Agency

Canada is a country of innovators. Curiosity, creativity and a collaborative spirit are what lead to the kinds of innovations and technologies that improve our daily lives and drive our economy, and our country, forward. That is why the Government of Canada is investing $5,000,000 in BioVectra Inc. to help the Charlottetown-based biotechnology and pharmaceutical ingredient manufacturing company expand its operations to Nova Scotia. This will enable the firm to grow, create additional highly skilled positions and help build sustained economic prosperity in Atlantic Canada.

The funding was announced today by the Honourable Scott Brison, Secretary of the Treasury Board and Member of Parliament for Kings-Hants, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA). The repayable contribution is being made through ACOA’s Business Development Program, which helps small and medium-sized enterprises expand and modernize to improve competitiveness.

BioVectra will use the assistance to complete major renovations at its Windsor facility and to purchase new equipment. This will allow the company to increase its capacity to develop and manufacture biologic drug substances for global pharmaceutical and biotechnology companies. These materials are used in the creation of products to treat cancer, autoimmune disorders, diabetes, arthritis, and many other serious illnesses.

The project will create 28 full-time positions, and by 2020, when the plant is fully operational, it is expected that more than double that number of people will be employed there.

This investment builds on commitments made by the Government of Canada and the four Atlantic Provinces to drive economic growth in the region through the Atlantic Growth Strategy, which supports strategic investments in initiatives that build on the region’s competitive advantages, such as its strong export potential, growing innovation network, and skilled workforce.

Follow ACOA on Twitter: @ACOACanada (twitter.com/acoacanada)

Quotes

“Science and technology – along with stronger international trade – are rapidly changing the way Canadians live and work, bringing new challenges and more opportunities. Investing in BioVectra Inc., an industry-leading biotechnology and pharmaceutical ingredient manufacturing firm, will help strengthen and grow the middle class, and lay a more solid foundation for the next generations of Canadians.”

  • The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA

“The jobs of the future depend on Canadians’ ability to continue to adapt, innovate, and maintain our competitive edge in the fast-paced and increasingly global economy. BioVectra is already known worldwide for its expertise in developing and producing active pharmaceutical ingredients used in products that treat life-threatening diseases.

This modern, 50,000 square-foot facility will increase the company’s manufacturing capacity by 40 per cent and allow BioVectra to become a rare one-stop shop for its global biotech and pharmaceutical customers.”

  • The Honourable Scott Brison, President of the Treasury Board and Member of Parliament for Kings-Hants

“As an integral part and leader within the vibrant Atlantic Canadian BioScience cluster, we consider ourselves fortunate to operate in a supportive ecosystem where substantial emphasis is placed on talent, skills and innovation. The contribution from ACOA’s Business Development program will enable BioVectra to continue to thrive, create highly skilled jobs in Atlantic Canada, and help solidify Canadian leadership within the very competitive global markets we participate in.”

  • Oliver Technow, President, BioVectra Inc.

Quick Facts

  • BioVectra Inc., headquartered in Charlottetown, P.E.I., has more than 300 employees, and will initially add another 28 jobs in Windsor. The company’s four locations – three in Charlottetown and one in Windsor – total approximately 110,000 square feet.
  • BioVectra’s predecessor, Diagnostic Chemicals Ltd. (DCL), was founded in 1970 by Dr. Regis Duffy, then a UPEI chemistry professor, who began producing small amounts of a specialty chemical under contract to a U.S. firm.
  • Since its inception, BioVectra, which is part of the active pharmaceutical ingredient life cycle from early clinical development to commercial supply, has created hundreds of products used on the market today.

Contacts

Alex Smith
Director of Communications and Outreach
Atlantic Canada Opportunities Agency
Phone: 902-426-9417 / 902-830-3839 (cell)
E-mail: alex.smith@canada.ca

Jordan MacGregor
Communications and Marketing Manager
BioVectra Inc.
Phone: 902-566-9116 ext 6376
E-Mail: jmacgregor@biovectra.com

To watch a video of the event via Scott Brison, click here.

April 12th, 2018|News|

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion

CHARLOTTETOWN, Prince Edward Island (12/14/2017) – BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease.

BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada.

“This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have cultivated in the Atlantic Canada region. We take great pride in serving the needs of global partners and the patients they are treating,” said BioVectra President, Oliver Technow. “We are very pleased to bring an agreement of this magnitude, creating highly skilled jobs, to Charlottetown, PEI. It is another terrific accomplishment for bioscience in Atlantic Canada.”

“With the recent U.S. FDA approval of Auryxia for a second indication, it is critical that we have sufficient manufacturing capacity to support anticipated future prescription demand,” said Melissa Bradford-Klug, Chief Business Officer of Keryx Biopharmaceuticals. “BioVectra has been manufacturing the active pharmaceutical ingredient in Auryxia since 2003 and we believe they will be a great partner as we continue to expand the supply chain for Auryxia.”

“This partnership illustrates what BioVectra does best. Since Keryx first approached us for clinical supply nearly 15 years ago,  we have collaborated on Auryxia’s clinical phases, registration, and commercial launch to a point where we are expanding capacity to meet increased market demand,” said Vice President of Business Development, Heather Delage. “We look forward to continuing to be an important part of Keryx’s long-term strategic supply chain.”

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com.

About BioVectra

BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • GMP Microbial Fermentation & Purification
  • Complex Chemistry
  • Process & Analytical Development

For more information about BioVectra, please visit www.biovectra.com.

Media Contact

Jordan MacGregor
Marketing and Communications Manager
jmacgregor@www.biovectra.com
902-566-9116 ext. 6376
www.biovectra.com

December 14th, 2017|Articles, News|

BioVectra Inc. Celebrates the Opening of Flagship Warehouse & Process Development Suites as part of Global Biotech Week

Charlottetown, Prince Edward Island (September 21, 2017) – BioVectra Inc. is proud to announce the opening of a new flagship warehouse and process development suites in Charlottetown, Prince Edward Island.

“A vibrant and successful BioScience cluster holds one of the keys to continued growth and prosperity for Canada,” BioVectra’s President Oliver Technow said. “BioVectra is well positioned as a leader in the highly competitive market we participate in, capitalizing on our unique capabilities, 300 tremendously skilled employees and unwavering commitment to quality.”

“The recent and future investments demonstrate our ability to remain competitive and to be at the global forefront of innovation and success, right here in Atlantic Canada,” Technow continued. “Our new, state-of-the-art warehouse meets our business needs of today and the future, exemplifying our dedication to grow further.”

“BioVectra is an excellent example of a company that is constantly adapting to the ever changing technological and scientific landscape in the bioscience industry,” Economic Development and Tourism Minister Heath MacDonald said. “It is a leader in an industry that is growing rapidly, adding new, highly skilled jobs, and gaining an international reputation for our province.”

BioVectra’s grand opening coincides with Global Biotech Week, a Canadian initiative that originated in 2003 to raise awareness of the industry and its global potential.

“Global Biotech Week provides an important opportunity to recognize and celebrate biotechnology innovation and the role it plays in addressing environmental and health challenges,” President and CEO of BIOTECanada Andrew Casey said. “Canada is one of a number of nations that are home to thriving and diverse biotechnology ecosystems which are developing game changing and life altering innovations.”

BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the biotechnology sector.

“BioVectra’s 45 year history, recent growth in Windsor, Nova Scotia and today’s addition of new warehouse and process development suites in Charlottetown, Prince Edward Island is a great example of a made in Canada globally competitive company,” Casey added. “The Canadian biotech ecosystem is supported by strong clusters in every province across the country offering Canadians competitive highly skilled 21st century jobs. All combined, the ecosystem is a strategic economic asset for Canada within the emerging global bio-economy.”

The new 21,000 square foot warehouse enhances BioVectra’s ability to grow with the global demand for its products and services. Equipped with 400 pallet positions, the new warehouse also provides the opportunity to grow with built-in expansions.

“As our business continues to grow, so does the need for storage of our raw materials, consumables and finished products,” BioVectra’s Planning and Operations Manager Tim Murphy said.

With a total investment of $4M, the new warehouse is equipped with a devoted loading dock, dedicated sampling rooms, robust security system and tight temperature controls to keep products at their required temperatures.

About BioVectra

BioVectra is a CDMO that serves pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable partner with a strong quality history, BioVectra has over 45 years of experience specializing in:

  • Microbial Fermentation
  • Complex Chemistry
  • High Potency APIs
  • Process & Analytical Development
  • Drug Development

Media Contact

Jordan MacGregor
Marketing and Communications Manager
jmacgregor@www.biovectra.com
902-566-9116 ext. 6376
www.biovectra.com

September 21st, 2017|Articles, News|

BioVectra Inc. to Open New Microbial Fermentation and Complex Chemistry Site in December 2017

$30 million investment increases BioVectra’s total manufacturing capacity by 40%

WINDSOR, Nova Scotia – BioVectra Inc., a Contract Development and Manufacturing Organization (CDMO) providing cGMP services to globally operated biotech and pharmaceutical companies, today announced that its fourth cGMP facility will be fully operational by December 2017. The late-stage to commercial-scale microbial fermentation and complex chemistry facility is located in Windsor, Nova Scotia, with proximity and service to Northeast USA development entities.

BioVectra’s $30 million investment has equipped the 50,000 square-foot facility with 40,000 liters (L) of fermentation capacity, downstream processing equipment and new pre-clinical fermentation and potent chemistry suites. “The investment strengthens our unique position in the very competitive global marketplace, enabling us to offer new and existing clients range of scale throughout the entire lifecycle of a product,” said Oliver Technow, BioVectra’s President.

The new facility is an investment in BioVectra’s core development and manufacturing competencies: microbial fermentation and complex chemistries. As an industry leader in microbial fermentation of both small and large molecules, the company provides scalable cGMP operations from 30 L to 17,000 L. BioVectra has the capability to handle the development and cGMP scale-up of high-potency active pharmaceutical ingredients (APIs), handling potent substances such as antibody-drug conjugate warheads, with occupational exposure limit (OEL) levels of < 20 ng/m3 (Safebridge Band 3 and 4).

The new facility increases BioVectra’s ability to partner with global pharmaceutical companies by offering dual-site risk mitigation. “This expansion helps BioVectra keep up with the growing demand for our products, while also meeting an underserved need for large-scale microbial fermentation in North America,” said Heather Delage, Vice President of Business Development. “In addition to the facility’s large-scale fermentation capability, the site also offers a complementary footprint for synthetic process development and laboratory-based activities.”

BioVectra’s three additional cGMP facilities and headquarters are located in Charlottetown, Prince Edward Island.

Media Contact 
Jordan MacGregor, 902-566-9116 ext. 6376
Communications Manager
jmacgregor@www.biovectra.com

May 24th, 2017|Articles|